文献速递乳腺癌支持与姑息治疗

Trastuzumab duocarmazine治疗局部晚期和转移性实体瘤及HER2表达乳腺癌:1期剂量递增和剂量扩展研究

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
PubMed 文献 · Lancet Oncol · 2019-06-27

该1期研究评估了新型HER2靶向抗体偶联药物trastuzumab duocarmazine在晚期实体瘤患者中的安全性和活性。

要点

  • HER2阳性乳腺癌客观缓解率33%,HER2低表达乳腺癌亦观察到缓解。
  • 常见治疗相关不良事件包括疲劳、结膜炎和干眼,多数为1-2级。

核心结论

  • Trastuzumab duocarmazine在经重度治疗的HER2表达转移性癌症中显示出显著临床活性,包括HER2阳性曲妥珠单抗 emtansine耐药和HER2低表达乳腺癌,安全性可控。

研究设计与样本

  • 1期剂量递增和剂量扩展研究,剂量递增阶段纳入39例局部晚期或转移性实体瘤患者,剂量扩展阶段纳入146例乳腺癌、胃癌、尿路上皮癌或子宫内膜癌患者。
  • 主要终点:剂量递增阶段为安全性和确定推荐2期剂量;剂量扩展阶段为客观缓解率(RECIST 1.1)。

主要发现

  • 剂量扩展阶段治疗相关严重不良事件报告16例(11%),最常见为输液相关反应(2例[1%])和呼吸困难(2例[1%])。
  • 剂量扩展阶段最常见治疗相关不良事件(1-4级)为疲劳(48例[33%])、结膜炎(45例[31%])和干眼(45例[31%])。
  • 104例(71%)患者发生至少1次眼部不良事件,3级事件10例(7%)。

临床怎么用

  • 对于HER2表达(包括HER2低表达)的转移性乳腺癌,trastuzumab duocarmazine显示出有希望的抗肿瘤活性。
  • 治疗期间需密切监测眼部不良事件,包括结膜炎、干眼和角膜炎。

局限性

  • 本研究为1期单臂研究,样本量有限,疗效需进一步随机对照试验验证。
  • 剂量扩展阶段纳入多种瘤种,各瘤种样本量较小。
  • 研究未报告无进展生存期和总生存期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour activity in various models. In this first-in-human study, we assessed the safety and activity of trastuzumab duocarmazine in patients with advanced solid tumours. METHODS: We did a phase 1 dose-escalation and dose-expansion study. The dose-escalation cohort comprised patients aged 18 years or older enrolled from three academic hospitals in Belgium, the Netherlands, and the UK with locally advanced or metastatic solid tumours with variable HER2 status who were refractory to standard cancer treatment. A separate cohort of patients were enrolled to the dose-expansion phase from 15 hospitals in Belgium, the Netherlands, Spain, and the UK. Dose-expansion cohorts included patients aged 18 years or older with breast, gastric, urothelial, or endometrial cancer with at least HER2 immunohistochemistry 1+ expression and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST). Trastuzumab duocarmazine was administered intravenously on day 1 of each 3-week cycle. In the dose-escalation phase, trastuzumab duocarmazine was given at doses of 0·3 mg/kg to 2·4 mg/kg (3 + 3 design) until disease progression or unacceptable toxicity. The primary endpoint of the dose-escalation phase was to assess safety and ascertain the recommended phase 2 dose, which would be the dose used in the dose-expansion phase. The primary endpoint of the dose-expansion phase was the proportion of patients achieving an objective response (complete response or partial response), as assessed by the investigator using RECIST version 1.1. This ongoing study is registered with ClinicalTrials.gov, number NCT02277717, and is fully recruited. FINDINGS: Between Oct 30, 2014, and April 2, 2018, 39 patients were enrolled and treated in the dose-escalation phase and 146 patients were enrolled and treated in the dose-expansion phase. One dose-limiting toxic effect (death from pneumonitis) occurred at the highest administered dose (2·4 mg/kg) in the dose-escalation phase. One further death occurred in the dose-escalation phase (1·5 mg/kg cohort) due to disease progression, which was attributed to general physical health decline. Grade 3-4 treatment-related adverse events reported more than once in the dose-escalation phase were keratitis (n=3) and fatigue (n=2). Based on all available data, the recommended phase 2 dose was set at 1·2 mg/kg. In the dose-expansion phase, treatment-related serious adverse events were reported in 16 (11%) of 146 patients, most commonly infusion-related reactions (two [1%]) and dyspnoea (two [1%]). The most common treatment-related adverse events (grades 1-4) were fatigue (48 [33%] of 146 patients), conjunctivitis (45 [31%]), and dry eye (45 [31%]). Most patients (104 [71%] of 146) had at least one ocular adverse event, with grade 3 events reported in ten (7%) of 146 patients. No patients died from treatment-related adverse events and four patients died due to disease progression, which were attributed to hepatic failure (n=1), upper gastrointestinal haemorrhage (n=1), neurological decompensation (n=1), and renal failure (n=1). In the breast cancer dose-expansion cohorts, 16 (33%, 95% CI 20·4-48·4) of 48 assessable patients with HER2-positive breast cancer achieved an objective response (all partial responses) according to RECIST. Nine (28%, 95% CI 13·8-46·8) of 32 patients with HER2-low, hormone receptor-positive breast cancer and six (40%, 16·3-67·6) of 15 patients with HER2-low, hormone receptor-negative breast cancer achieved an objective response (all partial responses). Partial responses were also observed in one (6%, 95% CI 0·2-30·2) of 16 patients with gastric cancer, four (25%, 7·3-52·4) of 16 patients with urothelial cancer, and five (39%, 13·9-68·4) of 13 patients with endometrial cancer. INTERPRETATION: Trastuzumab duocarmazine shows notable clinical activity in heavily pretreated patients with HER2-expressing metastatic cancer, including HER2-positive trastuzumab emtansine-resistant and HER2-low breast cancer, with a manageable safety profile. Further investigation of trastuzumab duocarmazine for HER2-positive breast cancer is ongoing and trials for HER2-low breast cancer and other HER2-expressing cancers are in preparation. FUNDING: Synthon Biopharmaceuticals.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019. PMID: 31257177. doi:10.1016/S1470-2045(19)30328-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。